Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure

间日疟原虫威胁着世界上一半的人口。虽然正在进行的消除疟疾工作是 成功地减轻了全球恶性疟疾的负担，但对P. 间日疟原虫。尤其是间日疟原虫在肝脏中休眠并导致复发的独特能力 几周或几个月后的感染极大地使消除疟疾的运动复杂化。在这里，我们建议进行 在柬埔寨严格控制的实地研究，专门为支持和支持最先进的技术而设计 基因组分析，以确定复发的频率和与催产素重新激活相关的因素， 以及严格评估不同剂量伯喹根治的疗效。我们的 研究将为间日疟原虫复发提供一个独特的视角，并有助于更好地了解如何 成功消灭了这种未被研究的寄生虫。

Plasmodium vivax threatens half of the world’s population. While on-going malaria elimination efforts are successfully reducing the burden of falciparum malaria worldwide, the situation is much less promising for P. vivax. In particular, the unique ability of P. vivax parasites to remain dormant in the liver and cause relapse infections weeks or months later greatly complicates malaria elimination campaigns. Here we propose to conduct a tightly-controlled field study in Cambodia, specifically designed to support and empower state-of-the-art genomic analyses, to determine the frequency of relapse and the factors associated with hypnozoite reactivation, as well as to rigorously evaluate the efficacy of different doses of primaquine for radical cure treatment. Our studies will provide a unique perspective on P. vivax relapse and will contribute to better understand how to successfully eliminate this understudied parasite.